Price (delayed)
$6.21
Market cap
$656.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.22
Enterprise value
$527.98M
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on
There are no recent dividends present for ANNX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.